U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07177872) titled 'A Long-term Efficacy and Safety of NTQ5082 Capsules' on Sept. 10.
Brief Summary: NTQ5082 capsules are a small molecule CFB inhibitor. This study is a multicenter, open-label study evaluating the long-term efficacy and safety of NTQ5082 capsules in the treatment of patients with paroxysmal nocturnal hemoglobinuria
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Paroxysmal Nocturnal Hemoglobinuria
Intervention:
DRUG: NTQ5082 capsules 200 mg
NTQ5082 capsules 200 mg
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical
Published by HT Digital Content Services with permissi...